EGFR and K-RAS mutations and ERCC1, TUBB3, TYMS, RRM1 and EGFR mRNA expression in nonsmall cell lung cancer: Correlation with clinical response to gefitinib or chemotherapy

By                    

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1123-1128

Science Publishers

Access to resources Recommend Favorite

Ultrasound-guided fine needle aspiration cytology of axillary lymph nodes in breast cancer patients. A preoperative staging procedure

By Kuenen-Boumeester V.   Menke-Pluymers M.   de Kanter A.Y.   Obdeijn I.-M.A.   Urich D.   Van Der Kwast T.H.  

European Journal of Cancer, Vol. 39, Iss. 2, 2003-01 ,pp. : 170-174

Elsevier

Access to resources Recommend Favorite

Detection of EGFR gene mutations in non-small cell lung cancer: Lessons from a single-institution routine analysis of 1,403 tumor samples

By            

International Journal of Oncology, Vol. 43, Iss. 4, 2013-01 ,pp. : 1045-1051

Spandidos Publications

Access to resources Recommend Favorite

Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients

By        

Oncology Reports, Vol. 30, Iss. 3, 2013-01 ,pp. : 1045-1052

Spandidos Publications

Access to resources Recommend Favorite

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite